## Suppl. Figure S1: Primer specifications relevant for this study.

Name	Primer Seq(5->3)		
Beta actin fwd	CCCAGCACAATGAAGATCAA		
Beta actin rev	CGATCCACACGGAGTACTTG		
Nestin F	GGCGCACCTCAAGATGTCC		
Nestin R	CTTGGGGTCCTGAAAGCTG		
SOX2_f	TGGACAGTTACGCGCACAT		
SOX2_r	CGAGTAGGACATGCTGTAGGT		
cd44-s-f	ATAATAAAGGAGCAGCACTTCAGGA		
cd44-s-r	ATAATTGTGTCTTGGTCTCTGGTAGC		
CA XII -F	ACTGCGGCAGGACTGAGTCT		
CA XII -R	CACAATACAGATGCCAAGAATGC		
CD133-F	GTGTCCTGGGGCTGCTGTTTA		
CD133-R	CCATTTTCCTTCTGTCGCTGG		
ZEB1-f	AAGAATTCACAGTGGAGAGAAGCCA		
ZEB1-r	CGTTTCTTGCAGTTTGGGCATT		

## Suppl. Figure S2: Antibody specifications relevant for this study.


Antibodies used in FACS

Primary Antibody	company	Host	addition	Dilution
		species		factor
CD133/1-PE, human	Miltenyi	Mouse	Monoclonal	1:200
CD133/1 Antibody, anti-	Biotech		Clone AC133	(5 µl/ml)
human, PE				
Anti-carbonic anhydrase XII	Sino	Mouse	Monoclonal	1:200
Antibody (FITC)	Biological		Clone #07	(0.5 µl/ml)


Antibodies used in western blot

Primary Antibody	company	Host	addition	Dilution
		species		factor
Anti-ZEB1 antibody	Sigma-Aldrich	Rabbit	Polyclonal	1:1000
beta-actin	Invitrogen	Mouse	Monoclonal	1:5000
GAPDH	Proteintech	Mouse	Monoclonal	1:8000
CA XII Antibody	Proteintech	Rabbit	Polyclonal	1:2000
CD133/1 (AC133)	Miltenyi Biotech	Mouse	Monoclonal	1:1000
antibody, human			(clone	
			W6B3C1)	
Secondary Antibody	company	species	addition	
IRDye 680RD Donkey	LiCor Biosciences	Donkey	Polyclonal	1:10000
anti-Mouse IgG				
IRDye 800CW Goat	LiCor Biosciences	Goat	Polyclonal	1:10000
anti-Rabbit IgG				

Suppl. Figure S3: Additional clinical datasets verified the significant clinical prognostic value of high CA12 mRNA to predict overall survival of glioma patients.



Suppl. Figure S4: **Biological function and** pathway enrichment analysis of CA12 in CGGA, CGGA 2019 and TCGA databases reveals association to networks known to be relevant for the maintenance of cancer stem cells.



Count

• 3

5

7

9

11

Count

• 5.0

0 7.5

0 10.0


12.5

15.0

5 4

3

Suppl. Figure S5: 6A10 treatment with no effect on proliferation, trend of induction of apoptosis in GBM1, no effect on cell cycle progression.



## Suppl. Figure S6: Low similarity between expression of CA family members in clinical samples

Unsupervised cluster analysis found that CA family members cannot be grouped stably in CGGA (A), CGGA 2019 (B) and TCGA (C) databases. Expression correlation matrix analysis found that CA family members have no stable expression correlation in CGGA (D), CGGA 2019 (E) and TCGA (F) databases.

